Vitiligo Working Group meeting in San Diego
Breaking down barriers to collaboration in vitiligo research
- Welcome word by Iltefat Hamzavi , MD Henry Ford Hospital, Detroit, Michigan, USA
- Update from Vitiligo Global Issues Consensus Conference National reference center for rare skin diseases - Dr Khaled EZZEDINE, Department of Dermatology, Hôpital St-André, CHU de Bordeaux
- Vitiligo surgery - overview and barriers to collaboration by - Davinder Prasad – Head of Vitiligo Surgery panel, Post Graduate Institute for Medical Sciences, Chandigar India
- Experience with the first two cases of non-cultured melanocyte transfer for vitiligo in South Africa - N Raboobee, University of KZN, Durban, South Africa
- John Harris, Panel leader for Basic Science of Vitiligo What we know about vitiligo basic science – barriers to collaboration. MD University of Massachusetts Medical School, Worcester, MA, USA
- Monitoring Treatment Outcomes in Vitiligo Non-Invasively Using Confocal Microscopy - Dr. Babar Rao
- CXCL10, an IFN-induced chemokine, is required for the development of depigmentation in a mouse model of vitiligo - Rashighi M, Agarwal P, Harris TH, Deng A, Hunter CA, and Harris JE - University of Massachusetts Medical School, Worcester, MA, USA, University of Pennsylvania, Philadelphia, PA, USA.
- Novel gene expression changes in the microenvironment of vitiligo lesional skin - Mingwan Su, Richard Yu, Xuejun Zhang, and Youwen Zhou - Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada
- Abrar Qureishi, Panel leader Epidemiology - barriers to collaboration
Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.
- Validation of a Vitiligo-Specific Health-Related Quality of Life (VitiQoL) Instrument - Roopal V. Kundu, MD - Department of Dermatology, Northwestern University, Chicago, IL, USA
- Co-morbidities associated with vitiligo: A 10-year retrospective study -
Vaneeta M Sheth, MD, Evie Guo, Abrar A Qureshi, MD/MPH Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.
- Henry Lim, Henry Ford Hospital, Detroit Michigan – Panel leader clinical research ,patient advocacy and increasing resources for vitiligo research Increasing support for Vitiligo basic science, epidemiologic and clinical research. What are the barriers to collaboration?
- A Proof of Concept Study to Compare the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light versus Narrow-Band Ultraviolet B (NB-UVB) Light Alone in the Treatment of Nonsegmental Vitiligo - Oma N. Agbai, M.D., Iltefat Hamzavi, M.D., Henry W. Lim, M.D., All authors affiliated with Henry Ford Hospital
I support the petition to designate June 25 as Vitiligo World Day and save millions of people worldwide from social isolation and persecution.
What causes vitiligo?
It remains unclear what causes damage to melanocytes and their subsequent total inactivation and/or disappearance in vitiligo skin. There are several theories; the mos...
Is it possible to stop the progression of vitiligo?
Vitiligo is progressive in 73% of cases and regressive in 1.3%. We usually explain to the patients that progression depends on the modality of the disease spreading: l...
I have vitiligo: will my children have vitiligo, too?
Although most cases of vitiligo are sporadic, familial clustering is not uncommon, and up to 20% of patients report on the affected relatives. In whites, the lifetime ...
How can I treat vitiligo?
Choosing a treatment for vitiligo can be difficult, sometimes overwhelming. In general, first-line therapy should be safe, effective, minimally invasive, and cost effi...